|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions:</b> The current results provided evidence that RRM2 might act as a novel target for ccRCC, and exploration of nonnucleoside, reversible, small-molecule inhibitors against RRM2 could be promising.
|
31118677 |
2019 |
|
Amyotrophic Lateral Sclerosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
<i>In silico</i> docking of 50000 compounds to the RRM domains of TDP-43 identified a small molecule (rTRD01) that (i) bound to TDP-43's RRM1 and RRM2 domains, (ii) partially disrupted TDP-43's interaction with the hexanucleotide RNA repeat of the disease-linked <i>c9orf72</i> gene, but not with (UG)<sub>6</sub> canonical binding sequence of TDP-43, and (iii) improved larval turning, an assay measuring neuromuscular coordination and strength, in an ALS fly model based on the overexpression of mutant TDP-43.
|
31241884 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor suppressive activity of PIWI-interacting RNA in human fibrosarcoma mediated through repression of RRM2.
|
30362638 |
2019 |
|
Adenocarcinoma of pancreas
|
0.020 |
Biomarker
|
disease |
BEFREE |
RRM2 gene silencing attenuates pancreatic adenocarcinoma cellular invasiveness and gemcitabine chemoresistance.
|
15300189 |
2004 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
RRM2 gene and protein expression varies by tumor type.
|
18941749 |
2009 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
RRM2 phosphoprotein interaction module construction in HCC can be a new route for studying the pathogenesis of HCC.
|
20798514 |
2010 |
|
Carcinoma, Transitional Cell
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RRM2 overexpression was associated significantly with muscularis propria invasion in UC patients who had undergone radical cystectomy (P=0.005).
|
21166702 |
2010 |
|
Urothelial Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RRM2 overexpression was associated significantly with muscularis propria invasion in UC patients who had undergone radical cystectomy (P=0.005).
|
21166702 |
2010 |
|
Colorectal Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
Ribonucleotide reductase small subunit M2B prognoses better survival in colorectal cancer.
|
21415168 |
2011 |
|
Malignant neoplasm of colon and/or rectum
|
0.030 |
Biomarker
|
disease |
BEFREE |
Ribonucleotide reductase small subunit M2B prognoses better survival in colorectal cancer.
|
21415168 |
2011 |
|
Colorectal Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
RRM2 represents a novel therapeutic target, thus highlighting the potential utility of RRM2 inhibitors in colorectal cancer with oncogenic KRAS.
|
21873171 |
2011 |
|
Malignant neoplasm of colon and/or rectum
|
0.030 |
Biomarker
|
disease |
BEFREE |
RRM2 represents a novel therapeutic target, thus highlighting the potential utility of RRM2 inhibitors in colorectal cancer with oncogenic KRAS.
|
21873171 |
2011 |
|
Malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy.
|
23719266 |
2013 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy.
|
23719266 |
2013 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy.
|
23719266 |
2013 |
|
Malignant tumor of cervix
|
0.030 |
Biomarker
|
disease |
BEFREE |
RRM2 is a new molecular marker for the diagnosis and clinical outcomes of cervical cancer.
|
24637958 |
2014 |
|
Cervix carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
RRM2 is a new molecular marker for the diagnosis and clinical outcomes of cervical cancer.
|
24637958 |
2014 |
|
cervical cancer
|
0.030 |
Biomarker
|
disease |
BEFREE |
RRM2 is a new molecular marker for the diagnosis and clinical outcomes of cervical cancer.
|
24637958 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
RRM2 protein expression correlated with higher tumor grade, advanced T stage and poor disease-specific survival.
|
24756820 |
2014 |
|
estrogen receptor-negative breast cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
RRM2 appears to be a promising prognostic biomarker and therapeutic target for ER-negative breast cancer patients.
|
25213022 |
2014 |
|
Tumor Cell Invasion
|
0.090 |
Biomarker
|
phenotype |
BEFREE |
RRM2 stimulation dose-dependently enhanced the invasion and migration of BGC823 cells.
|
27348973 |
2016 |
|
Malignant neoplasm of breast
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
RRM2 gene expression decreases in metastases when compared to primary breast cancer and could be suggested as a marker to trace breast cancer evolution.
|
28782484 |
2017 |
|
Breast Carcinoma
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
RRM2 gene expression decreases in metastases when compared to primary breast cancer and could be suggested as a marker to trace breast cancer evolution.
|
28782484 |
2017 |
|
Papillary Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
A 3-mRNA signatures consisting of ERG, RRM2, and EGF was constructed to predict survival in pRCC.
|
31348324 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A combination of radiotherapy with LINC00958 silencing, RRM2 downregulation or miR-5095 overexpression was found to inhibit cervical cancer cell proliferation and tumor growth, while promoting cell apoptosis both in vitro and in vivo.
|
31169309 |
2019 |